Diabetes Oral Medications/Anti-Diabetic Medications
Drugs used in treat diabetes mellitus by lowering glucose levels in the blood. With the exceptions of Insulin, exenatide, liraglutide and pramlintide, all are administered orally and are thus also called oral hypoglycemic agents or oral . There are different classes of anti-diabetic drugs, and their selection depends on the nature of the diabetes, age and situation of the person, as well as other factors.
is a disease caused by the lack of insulin. Insulin must be used in Type I, which must be injected.
is a disease of insulin resistance by cells. Type 2 diabetes mellitus is the most common type of diabetes. Treatments include (1) agents that increase the amount of insulin secreted by the pancreas, (2) agents that increase the sensitivity of target organs to insulin, and (3) agents that decrease the rate at which glucose is absorbed from the gastrointestinal tract.
Several groups of drugs, mostly given by mouth, are effective in Type II, often in combination. address the core problem in Type II diabetes—insulin resistance.
, also known as "," bind to PPARγ, a type of nuclear regulatory protein involved in transcription of genes regulating glucose and fat metabolism.
are drugs that increase insulin output from the pancreas. Meglitinides help the pancreas produce insulin and are often called "short-acting secretagogues".
are "diabetes pills" but not technically hypoglycemic agents because they do not have a direct effect on insulin secretion or sensitivity. Dipeptidyl peptidase-4 (DPP-4) inhibitors increase blood concentration of the incretin GLP-1 by inhibiting its degradation by dipeptidyl peptidase-4.
- Meglitinides – nateglinide (Nonsulfonylurea secretagogues)
- Biguanides – metformin (Insulin Sensitizers)
- Sulfonylureas - glimepiride, glipizide, glyburide ( Secretagogues)
- Thiazolidinediones (Tzd) – pioglitazone (Insulin Sensitizers)
- Alpha-glucosidase inhibitors – Acarbose (Diabetes Pills)
- Injectable Incretin mimetics
- Injectable Amylin analogues
- Glycosurics (sodium/glucose cotransporter 2 (SGLT2)Inhibitors)
Related Conference of Diabetes Oral Medications/Anti-Diabetic Medications
Diabetes Oral Medications/Anti-Diabetic Medications Conference Speakers
- Diabetic Eye Disease (Diabetic Retinopathy)
- Advanced Technologies & Treatments for Diabetes
- Cardiovascular Disorders
- Clinical Diabetes and Diagnostic Approaches
- Diabetes and its Treatment
- Diabetes Complications
- Diabetes Management
- Diabetes Oral Medications/Anti-Diabetic Medications
- Diabetic Kidney Disease (Diabetic Nephropathy)
- Diagnosis and Pathophysiology of Hypertension
- Emerging Focus in Diabetes Research
- Endocrine and Metabolic Syndrome Disorders
- Endocrine complications
- Endocrinology and Metabolic Syndrome
- Endocrinology Research and Development
- Endocrinology: Disorders & Treatment
- Genetics of Diabetes
- Gestational hypertension
- Hypertension & Stroke
- Hypertension and Diabetes
- Hypertensive Heart disease
- Metabolic Responses and Nutrition
- Pulmonary Hypertension
- Treatment & Management Of Metabolic Syndrome
Are you interested in
- Advance Treatment in Diabetes: - Diabetes & Endocrinology - 2019 (UAE)
- Clinical Endocrinology - Diabetes & Endocrinology - 2019 (UAE)
- Diabetes & Endocrinology - Diabetes & Endocrinology - 2019 (UAE)
- Endocrine and Diabetes Disorders - Diabetes & Endocrinology - 2019 (UAE)
- Endocrinology Glands and Hormones - Diabetes & Endocrinology - 2019 (UAE)
- Endocrinology: Male & Female Reproductive Health - Diabetes & Endocrinology - 2019 (UAE)
- Molecular & Cellular Endocrinology - Diabetes & Endocrinology - 2019 (UAE)
- Nursing Care for Diabetes - Diabetes & Endocrinology - 2019 (UAE)
- Pediatric Endocrinology - Diabetes & Endocrinology - 2019 (UAE)
- Pituitary and Neuroendocrinology - Diabetes & Endocrinology - 2019 (UAE)
- Types of Diabetes and its Complications - Diabetes & Endocrinology - 2019 (UAE)